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Abstract Article Info 
Introduction: ROS, a mechanism in CIS pathogenesis, causes toxicity when cisplatin is administered. 
Superoxide anion (O2-), a radical anion, part of ROS that is initially triggered after a part of oxygen enters a 
living cell. The main principle of this enzyme is to work as a protection against oxygen toxicity and plays a role 
as body catalyst. The p21 has a main function in the regulation of cell cycle progression. It is able to regulate 
cell proliferation through its association with PCNA and DNA polymerase accessory factor as a part of cell 
regulation and apoptosis. 
Objective: To study the effects of cisplatin on the increase or decrease of O2-, SOD, proliferation (MTT), 
apoptosis and cytoplasmic p21 expression in C666-1 cell lines. 
Methods: An experimental study with a post control group design and cisplatin in group dosages of 7.86 µg/mL, 
15.36 µg/mL and 30.72 µg/mL. 
Results: The mean difference of O2- in C666-1 cell lines between cisplatin groups was not significant (P value 
0.871, P>0.05). The mean difference of SOD in C666-1 cell lines was highly significant (P value 0.001, P<0.05) 
showing a significant increase of SOD. The mean difference of C666-1 cell lines proliferation (MTT) between 
cisplatin groups was not significant (P value 0.094, P>0.05). The mean difference of C666-1 cell lines apoptosis 
between cisplatin groups was not significant (P value 0.104, P>0.05). Cytoplasmic p21 highest expression was 
found at the 30.72 dosage obtained from 24 hours observation. 
Conclusion: Increase of SOD after a high dose of cisplatin administration, due to the balance between ROS 
production and detoxification process caused by antioxidants (SOD), will affect cancer cells to proliferate and 
survive. Increase of apoptosis at the highest dose found in this study, showed that apoptosis was induced by 
cisplatin. Therefore, antioxidant administration may be considered for nasopharyngeal cancer patients. 
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Cisplatin (CIS) is a highly effective drug acting as an antineoplastic 
agent with DNA alkylation that is used in various solid tumors. 
Cisplatin is a chemotherapy medication, derived from platinol, used to 
treat a number of cancers, including sarcoma, carcinoma (such as small 
cell lung carcinoma and ovarium carcinoma), lymphoma and germinal 
cell tumors. Platinol is the first unit from the platinum class that 
contains anticancer benefits, also includes carboplatin and oxaliplatin. 
Platinum complex reacts in vivo, by binding and causing a cross 
reaction of the DNA, that will finally trigger apoptosis (programmed 
cell death) [1,2,3]. 
Reactive oxygen species (ROS) is a mechanism known in the 
pathogenesis of CIS, which causes toxicity when cisplatin is 
administered. Cisplatin not only plays a role in DNA damage, but also 
causes side effects even when administered at a low dose, causing it to 
trigger programmed cell death (apoptosis) [4]. Oxidative stress is a 
condition where the number of free radicals inside the the body exceeds 
its capacity to neutralize, which causes to imbalance between ROS/RNS 
(Reactive Nitrogen Species) production and antioxidants [5, 6]. In 
general, oxidative stress is caused by: 1) decrease in antioxidants, 2) 
increase in ROS/RNS production.   
Superoxide anion is a radical anion (O_2-) that belongs to a group 
of ROS, initially triggered after a part of oxygen enters a living cell. 
Superoxide anion is produced because of several factors, which are: 1) 
UV ray exposure, 2) smoking, 3) environmental pollution, 4) radiation 
or oxidation from xanthin oxidase or NADPH oxidase. The ability of 
O_2-is to attack cellular components and cause damage to components 
of fat, protein and DNA. This is the cause of several diseases, including 
cancer, atherosclerosis, rheumatoid arthritis and damage to the liver and 
nervous system.  
Superoxide dismutase (SOD) is an enzyme that is widely 
distributed in all aerobic cells. The working mechanism of this enzyme 
is to protect against oxygen toxicity and play a role in as a catalyst in 
changing superoxide radicals (O_2-). There are two forms of SOD in 
the cells. The first form is found in the cytoplasm containing Cu and Zn 
(Cu/ZnSOD). SOD protects aerobic organisms in fighting unwanted 
effects caused by superoxide. This enzyme is found in all aerobic 
tissues, especially I the mitochondria and cytosol [7]. 
The p21 is a tumor suppressor with a weight of 21Kda, with a main 
function in the regulation of cell cycle progression. This action is 
achieved by blocking the bond between CDK and cyclin. P21 is also 
known as cyclin-dependent kinase 1, that has a role in the cellular 
process including cell cycle regulation, apoptosis and autophagy. As a 
cyclin-dependent kinase 1, it also can directly bind and block the 
activity of cyclin-CDK2, CDK1 and CDK4/6 complexes, leading in cell 
cycle blockage at resting phase. The bond between p21 and CDK is 
strengthened by the cyclin associated with CDK. P21 has a vital role as 
a cell cycle progress checkpoint, to prevent replication and decrease the 
amount of DNA damage in its sub-cells [8]. 
2. MATERIALS AND METHODS 
This is a laboratory experimental study with a post control group 
design. This study was conducted in the Biochemistry Laboratory and 
Pharmacology Laboratory, Faculty of Medicine, Brawijaya University, 







Malang City, after an ethical approval was signed. Laboratory 
experiment conducted in this study used C666-1 cell lines 
(undifferentiated nasopharyngeal carcinoma) provided by American 
Type Culture Collection (ATCC). To achieve a certain cisplatin dose, 
every group was tested three times under Lc50 [9]. According to a study 
cisplatin dose used in an in vitro study, using Hela cells, was 1-50 µM; 
achieving a toxic dose at 13 µM [10]. Those results were tested on 
C666-1 cell lines by observing the O_2-value (ABCAM Kit) and SOD 
activity (SOD Assay Kit (STA 340). Immunohistochemistry 
(monoclonal human antibody) examination was performed on C666-1 
cell lines by calculating the amount of staining. Thep21/WAF-1 
(SCYTEK TM) reagen was used to analyze p21 expression by the 
intensity of brown staining. Proliferation rate was analyzed by 
measuring MTT (cell Quanti-MTT TM(3-(4,5-dimethylthiazole-2-yl)-
2,5-siphenyltetrazolium bromide)) while flow cytometry was used to 
calculate apoptosis. (Apoptosis Kit (FTIC Anexin V Apoptosis 
Detection Kit)) using Image-based Cytometer.  
Data analysis performed to differentiate dependent variables in more 
than two unpaired data groups (or data from different subjects) was with 
one-way ANOVA test. This study was to explore the differences of 
superoxide anion, SOD, cell proliferation (MTT) and apoptosis in C666-1 
cell lines and experimented group after administration of cisplatin dosages 
of 7.86 µg/mL; 15.36 µg/mL and 30.72 µg/mL.  
 
3. RESULTS 
This study reported the effects of administration of different cisplatin dosages on 
superoxide anion, SOD, proliferation and apoptosis, analyzed based on F test 
using one-way ANOVA, as shown in the corresponding table. 
Table 1. Mean difference of superoxide anion(𝐎𝟐
-) in C666-1 cell lines 
between cisplatin dose groups of 7.86 µg/mL; 15.36 µg/mL 
and 30.72 µg/mL 
 
There was no significant difference (P > 0.05) found between cisplatin 
dose groups 7.86 µg/mL and 15.36 µg/mL (P = 0.941; P > 0.05), between 
cisplatin dose groups 7.86 µg/mL and 30.72 µg/mL (P = 0.863; P > 0.05), 
and between cisplatin dose groups 15.36 µg/mL and 30.72 µg/mL (P = 
0.980; P > 0.05). 
Table 2. Mean difference of SOD in C666-1 cell lines between cisplatin 
dose groups of 7.86 µg/mL; 15.36 µg/mL and 30.72 µg/mL 
Study Groups Mean of SOD Difference of SOD p-value 
Dose 7.86 vs dose 15.36 0.233 vs 0.804  0.5717  0.001 
Dose 7.86 vs dose 30.72 0.233 vs 0.839  0.6060     0.001 
Dose 15.36 vs dose 30.72 0.804 vs 0.839  0.0343 0.442 
F Test 336.179 
P value 0.001 
 
There was a highly significant difference (P < 0,01) between cisplatin dose 
groups 7.86 µg/mland15.36 µg/mL (P = 0.001; P < 0,01)and between 
cisplatin dose groups 7.86 µg/mLand30.72 µg/mL (P = 0,001; P< 0,01), but 
there was no significant difference found between cisplatin dose groups 
15.36 µg/mL and30.72 µg/mL (P = 0.442;  P > 0.05). 
 
Table 3. Mean difference of proliferation (MTT)in C666-1 cell lines 
between cisplatin dose groups 7.86 µg/mL; 15.36 µg/mL and 
30.72 µg/mL 
 
There was no significant difference (P > 0.05) found between cisplatin 
dose groups 7.86 µg/mLand15.36 µg/mL (P = 0.151; P > 0.05), between 
cisplatin dose groups 7.86 µg/mLand30.72 µg/mL (P = 0.111; P > 0.05), and 
between cisplatin dose groups 15.36 µg/mL and30.72 µg/mL (P = 0.968;  P> 
0.05). 
 
Table 4. Mean difference of apoptosis in C666-1 cell lines between 
cisplatin dose groups 7.86 µg/mL; 15.36 µg/mL and 30.72 
µg/mL 
Study Groups Mean Apoptosis Difference of Apoptosis p-value 
Dose 7.86 vs dose 15.36 20.387 vs 7243  13.1433 0.099 
Dose 7.86 vs dose 30.72 20.387 vs 11.047  9.3400 0.249 
Dose 15.36 vs dose 30.72 7.243 vs 11.047   3.8033 0.755 
Uji F 3.379 
P value 0.104 
 
There was no significant difference (P > 0.05) found between cisplatin 
dose groups 7.86 µ/mLand15.36 µg/mL  (P = 0.099; P > 0.05), between 
cisplatin dose groups 7.86 µg/mLand30.72 µg/mL (P = 0.249; P > 0.05), and 
between cisplatin dose groups 15.36 µg/mL and30.72 µg/mL (P = 0.755;  P 
> 0.05). 
After cisplatin administration dose of 7.86 µ/mL, there was nuclear 
p21 expression that started to release to the cytoplasm (24 hours). 





Difference of superoxide 
anion 
p-value 
Dose 7.86 vs dose 15.36 20.591 vs 22.242  1.6513 0.941 
Dose 7.86 vs dose 30.72 20.591 vs 23.176  2.5847 0.863 
Dose 15.36 vs dose 30.72 22.242 vs 23.176  0.9333 0.980 
F test 0.141 
P value 0.871 
Study Group Mean of MTT Difference of MTT p-value 
Dose 7.86 vs dose 15.36 76.459 vs 37.035  39.4233 0.151 
Dose 7.86 vs dose 30.72 76.459 vs 32.650  43.8090 0.111 
Dose 15.36 vs dose 30.72 37.035 vs 32.650   4.3857 0.968 
Uji F 3.604 
P value 0.094 







After cisplatin administration dose of 15.36 µ/mL, there was nuclear 
p21 expression that was released to the cytoplasm (brown staining 
partially filling the field of view) (24 hours). 
Picture 2. p21 expression results after cisplatin administration dose of 
15.36 µg/mL 
After cisplatin administration dose of 30.72 µ/mL, there was nuclear p21 
overexpression that was released to the cytoplasm (brown staining almost 
filling the field of view) (24 hours). 




Research data obtained after cisplatin administration in different 
dosages will increase superoxide anion, even though there was no 
significant difference statistically. Cisplatin will increase ROS, which will 
cause damage to fat cells and lead to failure of mitochondrial function [11, 
12]. In the past few years, several studies have tried to explain the 
relationship between cisplatin and the increase of ROS. ROS, in a smaller 
scale, plays a role in the apoptotic pathway, where the increase of ROS will 
change the mitochondrial potential membrane and destruct the cell’s 
respiratory chain, acting as the first trigger for apoptosis.  
Superoxide radicals play a main role in the cells as shown in table A, 
where it increases after cisplatin administration in different dosages. SOD 
also plays a role as a main element in. maintaining oxidant and antioxidant 
balance. SOD also functions in protecting aerobic organisms in fighting off 
side effects of superoxide. This enzyme can be found in all aerobic tissues, 
especially in the mitochondria and cytosol. SOD as an antioxidant enzyme 
(catalase [CAT], glutathion reductase [GSH-R], GSH peroxidase [GSH-
PX], glutathione-S-transferase and glutamyl cysteine synthetase) has a 
cytoprotective effect in fighting cisplatin side effects in in-vitro models, as 
performed in this study.   
There was a decrease of proliferation in C666-1 cell lines, as shown in 
this study, even though it was statistically insignificant, this can be explained 
by the ability of cisplatin to block proliferation of cancer cells. In other 
studies, there appears to be other proliferation pathwaysin C666-1 cell lines 
that causes MAPK(Mitogen Activated Protein Kinase) to promote cell 
growth and proliferation [13]. The p21 that was observed in this study was 
seen released from the nucleus, causing itunable to act as a tumor suppressor 
(shown as the brown staining in immunohistochemistry examination). The 
role of p21 after cisplatin administration in C666-1 cell lines, correlated with 
the function of p53 is still unclear. The role of cell cycle already began since 
the sensitization of cisplatin through mediation from down regulation in p53 
pathway to p21 (WAF1(Wild-type 53 activated fragment-1). The increase 
sensitivity of cisplatin was shown by the loss of contribution of p21 at the 
G2/M resting phase. This condition will result in premature cell mitosis and 
those cell lines will die before becoming mature. 
There was an increase and decrease of apoptosis in C666-1 cell lines 
after administration of cisplatin in different dosages even though it was 
statistically insignificant. The increase of apoptosis in C666-1 cell lines 
happened after the administration of cisplatin at30.72 µg/mL, compared to 
smaller dosages (7.86 µg/mL and 15.36 µg/mL), where decrease of 
apoptosis was found. This is similar to a previous study where cisplatin 
induces cell death through apoptosis and cause defect in the apoptotic 
pathway. There are 2 main mechanisms of cell apoptosis : 1) Extrinsic 
pathway, by bonding with tumor necrosis factor-α (TNFα) receptor super 
family, followed by procaspase 8 through intrinsic pathway molecule, 
thedeath-inducing signaling complex (DISC); 2) Intrinsic pathway, by 
initiating cell stress, for example where cytochrome-c is released from the 
mitochondria, causing activation of procaspase 9 through interactions with 
apoptosis promoting activating factor-1 (APAF-1) and formation of an 
active apoptosome complex. Bcl2 protein family regulates pathways where 
apoptosis is induced by DNA damage by releasing mitochondrial 
cytochrome-c in response to DNA damage [14]. Results obtained from this 
study may become the foundation of cisplatin dosage administration in 
cancer patients (nasopharyngeal carcinoma patients), where the maximum 
dosage will affect the cancer cell growth. Cisplatin will induce genotoxic 
stress in several biomolecular pathways related to apoptosis..  
5. CONCLUSION 
Cisplatin administration in different dosages will increase superoxide 
anion even though it was statistically insignificant. Cisplatin will increase 
ROS, as the cause of fat cell damage and failure to the mitochondrial 
function [15]. 
There was an increase of SOD after administration of a high dose of 
cisplatin where a balance of ROS production and detoxification process by 
antioxidants (SOD) occurred. 
Cisplatin administration in different dosages will block cancer cell 
proliferation (C666-1 cell lines) studied that there are other pathways related 
to MAPK that promotes cell proliferation. 
Increase of apoptosis in C666-1 cell lines occurred after cisplatin 
administration at the dose of 30.72 µg/ml in 24 hours. This is similar to a 
previous study where cisplatin induced cell death and caused defect in the 
apoptotic pathway. 
After cisplatin administration at the dose of 30.72 µ/mL, there was 
overexpression of nuclear p21 that was released to the cytoplasm (the brown 
staining filling the field of view) (after 24 hours) This shows that p21 was 
released from the nucleus to the cytoplasm indicating failure of cell 
checkpoint.  
This study revealed the effect of cisplatin agent in different dosages 
experimented in vitro in C666-1 cell lines. Cisplatin is an antineoplastic 
drug, acting as an alkylating agent, serving as an effective chemotherapy 
drug for nasopharyngeal carcinoma up to this date. One of the focal points 
of this study is the characteristic of cisplatin experimented on C666-1 cell 
lines. The purpose of this study is to prove the effect and role of cisplatin on 
the increase of superoxide anion and SOD even though balance was not yet 
achieved (needs further studies), the decrease of cell proliferation and the 
increase of apoptosis of NPC cells (C666-1 cell lines) will eventually give 
an exact image of cisplatin administration in NPC patients.  
Administration of antioxidants in the use of cisplatin may be considered 
to maintain the homeostasis function in healthy cells between oxidants and 
antioxidants after cisplatin administration in NPC patients.Using the 
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